On Monday, February 07, 2022 @ 6:00PM-7:00PM ET, come virtually listen to Jeff Galvin (Harvard '81 Economics; CEO of American Gene Technologies and VP/CEO/Director of various other private and public technology companies) discuss gene therapy vs. cell therapy, recombinant DNA, how cells are grown and manipulated for commercial products, genetically modified organisms, and international business, all with connections to food, beverage, agriculture, nutrition, healthcare, and general biotechnology.

American Gene Technologies (AGT) is a private company developing and commercializing genetic medicines targeting major diseases, including HIV/AIDS, Phenylketonuria (PKU) and Hepatocellular carcinoma (liver cancer, or HCC). Its drug candidates have achieved initial proof of concept in preclinical studies, are in clinical trials, and have potential to deliver cost-effective therapies that are better targeted and more potent with fewer side effects. AGT’s drugs will treat symptomatic diseases, but are intended to provide durable cures that extend the length and improve the quality of patients’ lives using its unique gene-delivery platform.

This event is co-hosted by two student organizations: biology-focused Michigan Synthetic Biology Team ("MSBT"), business-focused Bio-Tech, Entrepreneurship, and Coding Organization ("BECO"), and engineering-focused Food Industry Student Association ("FISA"). Please navigate to MSBT's, BECO's, and FISA's respective homepages linked on this post to learn more and join their email lists.